Biocad secures $240 million contract for production of drugs for Moscow region

20 November 2017

Biocad, one of Russia’s leading drugmakers, has been granted a contract for exclusive supplies of a number of anti-cancer drugs for the needs of the Moscow Department of Health for the period of 2021-2027, reports The Pharma Letter’s local correspondent.

The contract is worth 14 billion roubles ($240 million), and involves localization of production by the company on its site in the city of Zelenograd (Moscow region).

According to Biocad chief executive Dmitry Morozov, the value of investments in the project at the initial stage is estimated at 3 billion roubles, part of which will be provided by Russian banks in the form of a loan, while the remainder will be allocated from the own sources of the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK